DOR
Figure 1 · Panel D
Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Arnon P Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Anton W Langerak, Brenda Chyla, Relja Popovic, Yanwen Jiang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F Seymour
Blood 145(23) 2733-2745
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab (BR). We report the final analyses of MURANO (median follow-up, 7 years). Patients were randomized to VenR (venetoclax 400 mg daily for 2 years plus monthly rituximab for 6 months; n = 194) or BR (6 months; n = 195). In a substudy, patients with progressive disease (PD) received VenR as retreatment or crossover from BR. At the final data cut (3 August 2022), the median PFS with VenR was 54.7 months vs 17.0 months with BR. The 7-year PFS with VenR was 23.0%. The 7-year OS was 69.6% and 51.0%, respectively. Among VenR-treated patients with undetectable minimal residual disease (MRD; uMRD) and no PD at end of treatment (EOT; n = 83), the median PFS from EOT was 52.5 vs 18.0 months in patients with MRD at EOT (n = 35; P < .0001). Fourteen patients had enduring uMRD. Three distinct mutations in BCL2 in 4 patients were identified. In the substudy, 25 patients were retreated with VenR, and 9 patients crossed over to VenR; the median PFS was 23 and 27 months, and the best overall response rate was 72% and 89%, respectively. At the end of combination treatment (EOCT), after retreatment or crossover, 8 and 6 patients achieved uMRD, respectively. No new safety findings were observed. Overall, these final MURANO analyses support consideration of fixed-duration VenR therapy for patients with relapsed/refractory CLL. This trial was registered at www.clinicaltrials.gov as #NCT02005471.
5 个 Figure · 9 个 KM 面板
Figure 1. Kaplan-Meier estimates of efficacy end points in the overall intent-to-treat population. Investigator-assessed PFS (A), OS (B), EFS (C), and DOR (D). Log-rank test and Cox proportional hazards regression model were used to compare overall PFS and OS across treatment arms. EFS, event-free survival.
Figure 1 · Panel D
Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. Kaplan-Meier estimates of efficacy end points by MRD∗ response status at EOT in the overall intent-to-treat population. (A) PFS; (B) OS. Fisher’s exact test was performed to compare MRD status at EOCT and EOT. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10 –4 ]) and MRD + (≥10 –4 ).
Figure 3. Kaplan-Meier estimates by MRD status and MRD conversion among VenR-treated patients in the overall intent-to-treat population. (A) Time to MRD∗ conversion; (B) time from conversion to PD; (C) time from PD to next treatment. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10 –4 ]) and MRD + (≥10 –4 ).
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. Kaplan-Meier estimates by time to second PFS event. Investigator-assessed time to second PFS event for patients receiving subsequent therapy previously randomized to VenR and BR (A) and patients previously randomized to VenR and BR receiving subsequent therapy by treatment type (B).
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. Kaplan-Meier estimate of investigator-assessed PFS in the VenR retreatment population.
Figure 5 · Panel PFS
Panel PFS 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。